# Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

> **NCT05524935** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 37 (estimated)

## Conditions studied

- Uveal Melanoma
- Ocular Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05524935
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-11
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05524935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05524935, "Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05524935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*